BIIB Stock UPDATES Biogen Idec Inc (BIIB) 343.04 09/02/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 343.04 $BIIB

Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple

Biogen: Moving From Collaboration To Innovation
at Investor's Business Daily - Fri Aug 29, 3:14PM CDT
In an industry as risky as biotechnology, it's easy to stick with a proven formula. But sometimes, managing for success means changing your strategic direction to avoid falling into a rut. After two decades of successfully collaborating with other...

Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.

US CNS Disorders Drug Pipeline Insight 2014
M2 - Fri Aug 29, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.

Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...

Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
Business Wire - Tue Aug 26, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9th Annual Biotech Conference. The webcast will be live on Thursday, September 4, 2014 at 10:00a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

Economic Data Fuel Another All-Time High For S&P 500
at Investor's Business Daily - Tue Aug 26, 2:36PM CDT
A big jump in durable goods orders and a strong reading on consumer confidence from the Conference Board fueled modest gains for the stock market Tuesday. The Dow Jones industrial average led the way, rising 0.3%. Exxon Mobil (XOM), UnitedHealth...

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
Business Wire - Tue Aug 26, 7:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec's amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub). The ALS iHub is a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS by integrating research with clinical development. Dr. Johns reports directly to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.

Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
CNW Group - Tue Aug 26, 7:00AM CDT
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions -

Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...

Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs
at Investor's Business Daily - Mon Aug 25, 1:54PM CDT
Major averages held on to decent gains with a little over one hour remaining in Monday's session. After topping the 2000 level, the S&P 500 rallied 0.5%; the Dow Jones industrial average also gained 0.5% while the Nasdaq tacked on 0.3%. Nasdaq volume...

Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...

Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.

Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.

Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 32

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 24

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 56

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 44

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 210

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 136

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 106

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 20

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 41

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL NXTPAPER 70 Pro: Pioneering Eye-Care Technology Innovation

Updated Category News Views 159

TCL NXTPAPER 70 Pro Takes Center Stage at Award Ceremony TCL, a renowned name in the display technology sector, has recently celebrated a significant achievement. The TCL NXTPAPER 70 Pro smartphone has been awarded the esteemed Eye-Care Display Technology Gold Award during a prestigious ceremony. This momentous occasion unfolded at the renowned Global Top Brands Awards...

Continue Reading
Sky Quarry Advances Its Waste Asphalt Shingle Facility Plans

Updated Category News Views 97

Sky Quarry Advances Its Waste Asphalt Shingle Facility Plans Sky Quarry Inc. (NASDAQ: SKYQ) is making significant strides toward enhancing the waste-to-energy industry with its innovative Waste Asphalt Shingle Modular Facility. Situated in Woods Cross, Utah, this facility is currently at an impressive stage of completion, standing at 80%. This marks a pivotal moment for...

Continue Reading
Bell Canada’s Strategic Move to Redeem Debentures Early

Updated Category News Views 322

Bell Canada Announces Early Redemption of Debentures Bell Canada recently made an important announcement regarding its financial strategies that speak volumes about its commitment to prudent management. The company revealed plans to redeem its outstanding Cdn $750 million principal amount of 3.55% Debentures, Series M-41, before their maturity date. This redemption is set...

Continue Reading
Exciting Housing Announcement: Key Insights for Communities

Updated Category News Views 174

Anticipating New Housing Developments Media outlets are set to cover an important housing announcement with significant implications for local communities. This event highlights the collaboration between government officials and community leaders focused on addressing housing needs and enhancing infrastructure in various regions. Key Officials Present at the Event The...

Continue Reading
Innovative Partnership Aims at Transforming Material Research

Updated Category News Views 284

Exciting Collaboration to Enhance Material Research In a groundbreaking partnership, CAS, a division of the American Chemical Society, has joined forces with PetroChina Shanghai Advanced Materials Research Institute Co., Ltd. This collaboration aims to utilize the CAS SciFinder Discovery Platform™ to expedite the research and development of advanced chemical materials....

Continue Reading